The FDA just approved Mounjaro to reduce heart attack and stroke risk. Here's what Brazilian patients with diabetes and cardiovascular disease need to know about this major expansion in GLP-1 therapy.
The U.S. Food and Drug Administration approved tirzepatide, sold as Mounjaro, for a new indication that goes far beyond blood sugar control and weight loss. In October 2024, the FDA cleared Mounjaro to reduce the risk of major cardiovascular events — including heart attack, stroke, and cardiovascular death — in adults with established atherosclerotic cardiovascular disease (ASCVD). This is a significant milestone not just for the GLP-1 drug class, but for millions of Brazilian patients who rely on this medication or are considering it.
What the FDA Cardiovascular Approval Actually Means
The approval expanded Mounjaro's label based on results from the SURPASS-CV trial, a large cardiovascular outcomes study that enrolled more than 13,000 patients across multiple countries. The study compared tirzepatide against dulaglutide, another GLP-1 receptor agonist, in adults with type 2 diabetes and established cardiovascular disease. Patients receiving tirzepatide experienced a statistically significant reduction in major adverse cardiovascular events compared to those on dulaglutide. This makes tirzepatide the second GLP-1 based molecule — after semaglutida (Wegovy) — to earn a cardiovascular risk reduction indication from the FDA.
What sets this approval apart is that it does not require obesity or overweight as a criterion. The indication is tied to a confirmed diagnosis of ASCVD, which includes people who have already had a heart attack, stroke, or have documented plaque buildup in their arteries. That means patients with type 2 diabetes and a history of cardiovascular events may benefit, regardless of their current weight.
Weight Loss Indication vs. Cardiovascular Indication: Who Benefits?
Understanding the difference between these two approvals matters a lot in practice. The weight loss indication, which many patients pursue, requires a body mass index of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension or sleep apnea. The cardiovascular indication, by contrast, hinges entirely on having documented ASCVD — no BMI threshold applies.
For Brazilian patients, this distinction opens a door. A person with type 2 diabetes who had a heart attack five years ago but carries a BMI of 26 — technically in the "overweight" range, not the "obese" range — could potentially access Mounjaro through the cardiovascular indication once regulators in Brazil approve it. That is a meaningful expansion of who might benefit from this treatment.
What This Means for Patients in Brazil Right Now
Mounjaro already has regulatory approval in Brazil from ANVISA for the treatment of type 2 diabetes, available in injectable pen formulations across six dose strengths. Brazilian doctors can currently prescribe it for diabetes management, and many physicians already use it off-label for obesity when they deem it clinically appropriate.
However, the cardiovascular indication is not automatically valid in Brazil just because the FDA granted it. Each new therapeutic indication requires a separate submission and evaluation by ANVISA. At this time, the cardiovascular risk reduction indication for tirzepatide has not been approved by the Brazilian health authority. This means patients seeking Mounjaro for heart protection currently rely on their doctor's judgment under existing approved indications.
Patients with established cardiovascular disease who are managing diabetes or obesity should discuss with their cardiologist or endocrinologist whether Mounjaro fits their clinical profile today, while staying informed about regulatory updates in Brazil.
Health Insurance and SUS Access: What Changes and What Remains the Same
For those with private health insurance, the situation is nuanced. The Agência Nacional de Saúde Suplementar (ANS) mandates coverage for diabetes medications, but coverage for obesity treatments and expanded cardiovascular indications varies by operator and plan. The FDA's approval of the cardiovascular indication does not automatically translate into coverage by Brazilian insurers, though it can strengthen arguments for coverage once ANVISA approves the same indication locally.
For SUS users, the outlook is more complex. Incorporation into the public health system goes through CONITEC, which evaluates clinical efficacy, safety, and cost-effectiveness. Given that tirzepatide is among the higher-priced GLP-1 options currently available in Brazil, the budgetary impact of large-scale public distribution is substantial. There is no short-term timeline for Mounjaro to become available through SUS, and patients dependent on public healthcare should work with their physicians to explore available alternatives within the system.
Mounjaro vs. Wegovy: Comparing Cardiovascular Benefits for Brazilian Patients
Wegovy (semaglutida 2,4 mg) earned its cardiovascular risk reduction indication from the FDA in March 2024, based on the SELECT trial, which demonstrated approximately a 20% reduction in major adverse cardiovascular events in patients with obesity and prior cardiovascular disease. Both approvals represent a shift in how the medical community views GLP-1 drugs — from glucose-focused medications to therapies with broad cardiometabolic benefits.
The mechanisms differ. Tirzepatide acts on both GLP-1 and GIP receptors, while semaglutide acts only on GLP-1. Whether this mechanistic difference translates into clinically meaningful advantages for specific patient subgroups is still an active area of research. Brazilian patients should rely on their healthcare providers to determine which medication suits their individual clinical situation, factoring in comorbidities, side effect profiles, and eventual local availability and cost.
For more updates on GLP-1 medications, regulatory changes, and practical guidance, keep following OzemNews — your source for clear, grounded reporting on the evolving landscape of weight and cardiometabolic health.
FAQ
Did the FDA approve Mounjaro specifically for heart disease?
Yes. In October 2024, the FDA approved tirzepatide (Mounjaro) to reduce the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with established atherosclerotic cardiovascular disease, independent of weight loss outcomes.
Can Brazilian patients already use Mounjaro for heart protection?
Not under a cardiovascular indication. Mounjaro is approved in Brazil for type 2 diabetes. The cardiovascular risk reduction indication has not yet been approved by ANVISA and requires a separate regulatory evaluation.
Is Mounjaro covered by health insurance in Brazil for heart-related use?
Coverage depends on the operator and plan. The ANS mandates diabetes coverage, but expanded cardiovascular indications are not automatically covered. Coverage may become more accessible once ANVISA approves the same indication.
What's the difference between Mounjaro and Wegovy for heart health?
Both have FDA approval to reduce cardiovascular risk. Mounjaro acts on GLP-1 and GIP receptors; Wegovy acts only on GLP-1. Wegovy's cardiovascular data came from the SELECT trial; Mounjaro's came from SURPASS-CV. The best choice depends on each patient's individual medical profile.
Will Mounjaro become available through Brazil's SUS?
Incorporation into SUS would require evaluation and approval by CONITEC, which considers cost-effectiveness and budget impact. Given current pricing, there is no clear timeline for public access to tirzepatide through the Brazilian public health system.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app
